Article in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
9 authors.
Leonie BrockmannDepartment of Systems Biology, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA.ORCID 0000-0002-7789-7616
Carlotta RondaDepartment of Systems Biology, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA.ORCID 0000-0002-7501-914X
Logan T SchwanzDepartment of Systems Biology, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA.
Yiming QuDepartment of Systems Biology, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA.ORCID 0009-0006-5327-8198
Daniel W ShneiderDepartment of Systems Biology, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA.ORCID 0009-0000-1602-1787
Chrystal F MavrosDepartment of Systems Biology, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA.ORCID 0000-0003-3914-7512
Ivaylo I IvanovDepartment of Microbiology and Immunology, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA.ORCID 0000-0001-5337-3386
Govind BhagatDepartment of Pathology and Cell Biology, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA.ORCID 0000-0001-6250-048X
Harris H WangDepartment of Systems Biology, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA.ORCID 0000-0003-2164-4318
Funding
The Organoid and Cell Culture CoreP30DK132710 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Robert F. Schwabe · 2022 to 2026
$7.2M
Role of intestinal commensal-induced Th17 cells and mucosal immunity in metabolic diseaseR01DK098378 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Ivaylo Ivanov Ivanov · 2013 to 2026
$6.5M
Micron-scale Spatial Metagenomic Mapping of Microbial Biogeography in the Gastrointestinal TractR01AI132403 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Harris H Wang · 2017 to 2026
$6.0M
The Role of Secondary Bile Acids in Gastro-Esophageal NeoplasiaR01CA272898 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Julian Abrams, Michael Quante · 2022 to 2026
$4.1M
Ecological dynamics and metabolic interactions in thegut microbiome across space and timeR01DK118044 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI VITKUP, DENNIS, WANG, HARRIS H · 2018 to 2022
$3.4M
A high-performance and versatile technology for precision microbiome engineeringR01EB031935 · NIBIB · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Samuel Henry Sternberg, Harris H Wang · 2021 to 2026
$3.3M
Maintenance of mucosal homeostasis by commensal Th17 cellsU01AI163069 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Ivaylo Ivanov Ivanov · 2021 to 2026
$2.8M
Discovery of immunomodulatory gut microbes with MAGICR21AI146817 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI IVANOV, IVAYLO IVANOV · 2019 to 2020
Western diets reduced in fiber promote dysbiosis and exacerbate colitis, with short-chain fatty acids (SCFAs) from fiber fermentation known to regulate glucagon-like peptide 1 (GLP-1) secretion. Whether GLP-1 dysregulation directly links diet-induced dysbiosis to colitis severity, and if this pathway can be therapeutically targeted independently of dietary fiber, remains unclear. Here, we show that dextran sulfate sodium (DSS)-induced colitis severity correlates with compensatory GLP-1 increases, while receptor blockade worsens damage, confirming GLP-1's protective role during colitis. Fiber deficiency impaired L cell function and GLP-1 release, increasing colitis susceptibility. GLP-1 receptor agonist reversed these effects, restoring barrier integrity and accelerating recovery. We engineered a probiotic, releasing a microbial peptide, that locally elevates GLP-1, which normalized gut parameters in fiber-deprived mice and alleviated colitis via GLP-1-dependent mechanisms, including improved metabolism, antimicrobial defenses , and barrier restoration. Our findings mechanistically connect fiber deficiency to colitis through GLP-1 and demonstrate that probiotic-mediated GLP-1 modulation can bypass dietary fiber requirements to maintain gut homeostasis.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Engineered probiotic restores GLP-1 signaling to ameliorate fiber-deficiency exacerbated colitis. · full record | OpenQuestion